Get the Stockscreener App
8.13
0.49%
-0.04
After Hours:
8.13
Cartesian Therapeutics Inc stock is traded at $8.13, with a volume of 115.65K.
It is down -0.49% in the last 24 hours and down -20.22% over the past month.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.
See More
Previous Close:
$8.17
Open:
$8.13
24h Volume:
115.65K
Relative Volume:
1.33
Market Cap:
$211.40M
Revenue:
$26.00M
Net Income/Loss:
$-219.71M
P/E Ratio:
-0.1633
EPS:
-49.8
Net Cash Flow:
$-51.37M
1W Performance:
-8.14%
1M Performance:
-20.22%
6M Performance:
-35.98%
1Y Performance:
-58.69%
1-Day Range:
$7.945
$8.29
1-Week Range:
$7.88
$8.89
52-Week Range:
$7.75
$26.50
Cartesian Therapeutics Inc Stock (RNAC) Company Profile
Name
Cartesian Therapeutics Inc
Sector
Industry
Phone
301-348-8698
Address
7495 NEW HORIZON WAY, FREDERICK
Compare RNAC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNAC
Cartesian Therapeutics Inc
|
8.13 | 212.44M | 26.00M | -219.71M | -51.37M | -49.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Initiated | Wedbush | Outperform |
| Dec-19-24 | Initiated | BTIG Research | Buy |
| Aug-06-24 | Initiated | TD Cowen | Buy |
| Jul-02-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-04-24 | Initiated | Oppenheimer | Outperform |
| May-24-24 | Initiated | Mizuho | Buy |
| Apr-23-24 | Reiterated | H.C. Wainwright | Buy |
| Apr-23-24 | Initiated | Leerink Partners | Outperform |
| Aug-18-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Jun-14-22 | Reiterated | Needham | Buy |
| Jun-06-22 | Initiated | SVB Leerink | Outperform |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Jan-26-21 | Upgrade | Mizuho | Neutral → Buy |
| Oct-01-20 | Downgrade | Mizuho | Buy → Neutral |
| Oct-01-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-12-20 | Downgrade | Stifel | Buy → Hold |
| Apr-28-20 | Initiated | H.C. Wainwright | Buy |
| Jan-29-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-21-20 | Initiated | William Blair | Outperform |
| Jun-27-18 | Initiated | Janney | Buy |
| Mar-30-17 | Reiterated | UBS | Buy |
View All
Cartesian Therapeutics Inc Stock (RNAC) Latest News
Cartesian Therapeutics Inc expected to post a loss of 84 cents a shareEarnings Preview - TradingView
Is a relief rally coming for Cartesian Therapeutics Inc. holdersJuly 2025 Momentum & Stepwise Entry/Exit Trade Alerts - newser.com
How Cartesian Therapeutics Inc. (1S70) stock expands through international marketsWeekly Investment Report & Free Low Drawdown Momentum Trade Ideas - newser.com
Is Cartesian Therapeutics Inc. trending in predictive chart modelsQuarterly Portfolio Review & Weekly Hot Stock Watchlists - newser.com
Key metrics from Cartesian Therapeutics Inc.’s quarterly dataPortfolio Update Summary & Consistent Profit Trading Strategies - newser.com
How Cartesian Therapeutics Inc. stock performs during Fed tightening cyclesDay Trade & AI Forecasted Entry/Exit Points - newser.com
What makes Cartesian Therapeutics Inc. (1S70) stock appealing to growth investorsJuly 2025 Analyst Calls & Free Accurate Trade Setup Notifications - newser.com
Is Cartesian Therapeutics Inc. a candidate for recovery playTrade Volume Summary & AI Enhanced Trading Alerts - newser.com
Will Cartesian Therapeutics Inc. price bounce be sustainableVolume Spike & Daily Growth Stock Tips - newser.com
How to read the order book for Cartesian Therapeutics Inc.2025 Market WrapUp & Community Trade Idea Sharing - newser.com
Will Cartesian Therapeutics Inc. stock outperform tech sector in 2025Entry Point & High Conviction Buy Zone Picks - newser.com
Working capital per share of Cartesian Therapeutics, Inc. – FWB:1S70 - TradingView
Is Cartesian Therapeutics Inc. stock near bottom after declineWeekly Risk Summary & Short-Term Swing Trade Alerts - newser.com
Combining price and volume data for Cartesian Therapeutics Inc.Quarterly Earnings Summary & Long-Term Capital Growth Ideas - newser.com
Is Cartesian Therapeutics Inc. stock supported by strong fundamentalsJuly 2025 Setups & Daily Volume Surge Trade Alerts - newser.com
Will Cartesian Therapeutics Inc. (1S70) stock gain from green policiesBear Alert & Verified Trade Idea Suggestions - newser.com
Cartesian Therapeutics, Inc. (RNAC) Analyst insights, Price targets and Recommendations - Yahoo! Finance Singapore
Cartesian Therapeutics (RNAC) Expected to Announce Earnings on Thursday - MarketBeat
Cartesian Therapeutics Announces Leadership Changes - The Globe and Mail
Ranking Cartesian Therapeutics Inc. among high performing stocks via tools2025 Momentum Check & Safe Investment Capital Preservation Plans - newser.com
What indicators show strength in Cartesian Therapeutics Inc.Portfolio Risk Summary & Daily Volume Surge Signals - newser.com
Cartesian Therapeutics Appoints Carsten Brunn, Ph.D., as Board Chairman - citybiz
Cartesian Therapeutics, Inc. Announces Board and Committee Changes, Effective from October 29, 2025 - MarketScreener
Cartesian Therapeutics (RNAC) Grants Stock Options to New Employ - GuruFocus
Cartesian Therapeutics Advances SLE Treatment with Descartes-08 Study - MSN
Cartesian Therapeutics Announces New Employment Inducement Grants - The Manila Times
Cartesian Therapeutics Announces Carsten Brunn, Ph.D., Named as Chairman of the Company’s Board of Directors - The Manila Times
Cartesian Therapeutics Announces Board Changes - TradingView
[8-K] Cartesian Therapeutics, Inc. Reports Material Event | RNAC SEC FilingForm 8-K - Stock Titan
Cartesian Therapeutics (NASDAQ: RNAC) grants options at $8.85 and $8.20 inducement - Stock Titan
Cartesian Therapeutics (NASDAQ: RNAC) appoints CEO Carsten Brunn as chairman - Stock Titan
Cartesian Therapeutics Inc Stock (RNAC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):